We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TRGP:NYSETarga Resources, Inc. Analysis

Data as of 2026-03-10 - not real-time

$234.74

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Targa Resources is trading well above its 20‑day, 50‑day and 200‑day moving averages, with the price sitting near $235 and a bullish trend direction, while the RSI hovers around the mid‑60s indicating upward momentum. Technical momentum is supported by a solid support level around $210 and a resistance ceiling near $250, though the MACD histogram has turned negative, hinting at a potential short‑term pullback. Volatility is elevated at roughly 24% over the past 30 days, and beta is close to 1, suggesting the stock moves in line with the broader market.
Fundamentally, the company posted a revenue decline of about 8% year‑over‑year, yet delivered a 20% jump in EBITDA and announced a $5.5 billion capex plan for 2026. The dividend of $1.00 per share (1.7% yield) is backed by a 44% payout ratio, but the balance sheet is heavily leveraged with a debt‑to‑equity ratio exceeding 500%, and free cash flow remains negative. Valuation metrics—PE of 27.6 versus an industry average of 20.6 and a DCF fair value far below the current price—signal that the stock is priced on the high side, despite a strong “strong buy” analyst consensus and an outlook for record earnings.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages and strong technical momentum
  • Attractive dividend yield with sustainable payout
  • Upcoming earnings beat and capex‑driven growth

Medium Term

1–3 years
Neutral
Model confidence: 8/10

Key Factors

  • Projected EBITDA growth and record 2026 outlook
  • High leverage and overvalued multiples
  • Potential for price correction toward fair value

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Stable cash‑flow generation from midstream operations
  • Continued dividend income supporting total return
  • Elevated debt levels and valuation premium requiring caution

Key Metrics & Analysis

Financial Health

Revenue Growth-7.90%
Profit Margin11.29%
P/E Ratio27.6
ROE51.38%
ROA8.68%
Debt/Equity548.63
P/B Ratio16.4
Op. Cash Flow$3.9B
Free Cash Flow$-264400000
Industry P/E20.6

Technical Analysis

TrendBullish
RSI64.8
Support$209.60
Resistance$250.00
MA 20$230.23
MA 50$205.60
MA 200$176.43
MACDBearish
VolumeStable
Fear & Greed Index79.75

Valuation

Fair Value$95.49
Target Price$242.45
Upside/Downside3.28%
GradeOvervalued
TypeGrowth
Dividend Yield1.70%

Risk Assessment

Beta0.97
Volatility23.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.